243 related articles for article (PubMed ID: 27264717)
1. Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid.
Sriraman SK; Salzano G; Sarisozen C; Torchilin V
Eur J Pharm Biopharm; 2016 Aug; 105():40-9. PubMed ID: 27264717
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
3. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
4. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
Yuan M; Qiu Y; Zhang L; Gao H; He Q
Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats.
Gaspar MM; Radomska A; Gobbo OL; Bakowsky U; Radomski MW; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2012 Dec; 25(6):310-8. PubMed ID: 22857016
[TBL] [Abstract][Full Text] [Related]
8. Targeted magnetic liposomes loaded with doxorubicin.
Pradhan P; Banerjee R; Bahadur D; Koch C; Mykhaylyk O; Plank C
Methods Mol Biol; 2010; 605():279-93. PubMed ID: 20072888
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
10. Preparation and anti-cancer activity of transferrin/folic acid double-targeted graphene oxide drug delivery system.
Lu T; Nong Z; Wei L; Wei M; Li G; Wu N; Liu C; Tang B; Qin Q; Li X; Meng F
J Biomater Appl; 2020 Jul; 35(1):15-27. PubMed ID: 32202183
[TBL] [Abstract][Full Text] [Related]
11. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
Malhi SS; Budhiraja A; Arora S; Chaudhari KR; Nepali K; Kumar R; Sohi H; Murthy RS
Int J Pharm; 2012 Aug; 432(1-2):63-74. PubMed ID: 22531856
[TBL] [Abstract][Full Text] [Related]
12. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
13. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
14. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
15. A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery.
Tang J; Wang Q; Yu Q; Qiu Y; Mei L; Wan D; Wang X; Li M; He Q
Acta Biomater; 2019 Jan; 83():379-389. PubMed ID: 30395963
[TBL] [Abstract][Full Text] [Related]
16. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
18. Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.
Pattni BS; Nagelli SG; Aryasomayajula B; Deshpande PP; Kulkarni A; Hartner WC; Thakur G; Degterev A; Torchilin VP
Pharm Res; 2016 Oct; 33(10):2540-51. PubMed ID: 27351426
[TBL] [Abstract][Full Text] [Related]
19. A Novel Folate-Targeted Nanoliposomal System of Doxorubicin for Cancer Targeting.
Lohade AA; Jain RR; Iyer K; Roy SK; Shimpi HH; Pawar Y; Rajan MG; Menon MD
AAPS PharmSciTech; 2016 Dec; 17(6):1298-1311. PubMed ID: 26689406
[TBL] [Abstract][Full Text] [Related]
20. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres.
Shen Z; Li Y; Kohama K; Oneill B; Bi J
Pharmacol Res; 2011 Jan; 63(1):51-8. PubMed ID: 21035550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
